Market Overview

FBR Capital Upgrades AMAG Pharmaceuticals To Outperform

Related AMAG
32 Stocks Moving In Friday's Pre-Market Session
46 Biggest Movers From Yesterday

Analysts at FBR Capital upgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Market Perform to Outperform.

The target price for AMAG Pharmaceuticals has been raised from $21 to $36.

AMAG Pharmaceuticals shares have surged 36.08% over the past 52 weeks, while the S&P 500 index has gained 16.68% in the same period.

AMAG Pharmaceuticals' shares jumped 28.21% to close at $29.72 yesterday.

Latest Ratings for AMAG

Feb 2018Janney CapitalUpgradesNeutralBuy
Nov 2017Morgan StanleyMaintainsOverweight
Oct 2017PiperJaffrayInitiates Coverage OnNeutral

View More Analyst Ratings for AMAG
View the Latest Analyst Ratings

Posted-In: FBR CapitalUpgrades Analyst Ratings


Related Articles (AMAG)

View Comments and Join the Discussion!